• Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market
  • According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by  P&S Market Research) around $29 billion were assigned to pharmaceutical products, feed additives and vaccines in 2014.
  • The same report forecasts for this segment up to $44 billion by 2020, with a CAGR of 7.0%
  • The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics
  • Broadening its portfolio Bionaturis Group strengthens its position as a reference partner to develop biological products for animal health from livestock to pets, having presence in the main markets at geographic, species and diseases level

 

Jerez de la Frontera, October 6th 2015. Bionaturis Group (ticker BNT) has recently unveiled up to six new biotech developments broadening its products portfolio, now accounting for more than twenty compounds in different developing stages for both human and animal health.

Five of these new products are devoted to veterinarian sector, pointing to several high-relevance diseases in livestock and pets, such as atopic dermatitis, osteoarthritis (or arthrosis) and different types of cancer, enhancing the Group position as a benchmark partner in the development of biological products for animal health.

The new unveiled products are:

Lead

Description

Indication

Specie

Stage

BNT014 Tailored universal VLP-vaccine Prevention of common cold (rhinovirus) Humans Proof of concept in vivo
BNT015 Recombinant VPL Vaccine Viral infection Swine Proof of concept in vivo
BNT018 Recombinant VPL Vaccine Rabbit Hemorrhagic Fever Rabits Proof of concept in vivo
BNT020 Feline recombinant interferon omega (bio-better) Antiviral, antiproliferative, immunomodulatory Dogs and cats Proof of concept in vivo
BNT021 Low molecular weight antibody-like antagonist Atopic dermatitis, osteoarthitis Dogs, cats and horses Proof of concept
BNT022 Low molecular weight antibody-like antagonist Anti-cancer Dogs and cats Proof of concept

 

Animal Health sector, a growing market

According to “Global Animal Healthcare Market Size, Share, Development, Growth and Demand Forecast to 2020” report (by  P&S Market Research) the global Animal Health sector represented an annual figure of $100 billion in 2014, being around $29 billion assigned to pharmaceutical products, feed additives and vaccines. The same report expects this segment to increase up to $44 billion by 2020, with a CAGR of 7.0%

The population growth and standard of living, resulting on a higher consumption of milk and meat and an increasing trend of adopting pets are some of the main robust drivers for the growth of the Animal Health market, which has nowadays a booming demand on both biological products and compounds devoted to reduce the use of traditional antibiotics

As opposed to the human sector, the developments in Animal Health require less investment and time and represent a low degree of uncertainty with a high R&D return of investment. At the same time, the role of third-party payers is very limited in this industry, so the interactions with the customers, the decision and also the payment is direct from them to the companies in the animal health industry.

 The unveiled new medicines

It is noteworthy the significant increase of products addressed to pets (BNT020, BNT021 and BNT022) within the company portfolio, joining to the already known BNT005, a first-in-class vaccine with double effect (preventive and therapeutic) devoted to combat visceral canine leishmaniasis.

The pets market presents a healthy and steady growth being the United States the single largest pet market with a $58 billion global expenditure in 2014, where 68% of U.S. households have a pet (96 million of cats and 83 million of dogs; 85 million cats and 74 million dogs in Europe –source APPA). Only in the States, the market for canine osteoarthritis (the target market for BNT021) accounted for $260 million on sales in 2014, while $200 million were estimated for atopic dermatitis. About chemotherapy treatments (BNT022 target), the average cost in USA is between $2,500 and $10,000 per animal.

With these new developing products, Bionaturis Group enhances its position in one of the most lucrative sectors within Animal Health, presenting a clear value proposition for underserved diseases, species and markets.

About Bionaturis Group

Bionaturis Group offers cutting-edge biotechnological products and services for human and animal health, being considered an international benchmark in second generation vaccine developments. The biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).

TO DOWNLOAD THE PRESS RELEASE, PLEASE CLICK HERE

 

Disclaimer

The Market and investors are informed that the Company’s developments are subject to significant risks and uncertainties, that include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Bionaturis’ ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Bionaturis’ patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 Currently, there are no guarantees that the development product will receive the necessary regulatory approvals or that they will prove to be commercially successful.